WO2013014405A3 - Methods of inhibiting inflammation comprising inhibiting cd63 - Google Patents

Methods of inhibiting inflammation comprising inhibiting cd63 Download PDF

Info

Publication number
WO2013014405A3
WO2013014405A3 PCT/GB2012/000605 GB2012000605W WO2013014405A3 WO 2013014405 A3 WO2013014405 A3 WO 2013014405A3 GB 2012000605 W GB2012000605 W GB 2012000605W WO 2013014405 A3 WO2013014405 A3 WO 2013014405A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting
reducing
methods
inflammation
relates
Prior art date
Application number
PCT/GB2012/000605
Other languages
French (fr)
Other versions
WO2013014405A2 (en
Inventor
Daniel F. CUTLER
Emily L. DOYLE
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of WO2013014405A2 publication Critical patent/WO2013014405A2/en
Publication of WO2013014405A3 publication Critical patent/WO2013014405A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

The invention relates to methods of inhibiting inflammation in a system comprising reducing or inhibiting CD63 in said system, wherein said inflammation is IgE-negative. The invention also relates to methods for inhibiting leukocyte recruitment in a system, inhibiting leukocyte rolling in a system, or inhibiting leukocyte extravasation in a system comprising reducing or inhibiting CD63 in said system. The invention also provides a method of reducing P-selectin levels comprising reducing or inhibiting CD63, and a method of reducing P-selectin clustering comprising reducing or inhibiting CD63.
PCT/GB2012/000605 2011-07-22 2012-07-20 Methods WO2013014405A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201112718A GB201112718D0 (en) 2011-07-22 2011-07-22 Methods
GB1112718.0 2011-07-22

Publications (2)

Publication Number Publication Date
WO2013014405A2 WO2013014405A2 (en) 2013-01-31
WO2013014405A3 true WO2013014405A3 (en) 2013-05-30

Family

ID=44652232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2012/000605 WO2013014405A2 (en) 2011-07-22 2012-07-20 Methods

Country Status (2)

Country Link
GB (1) GB201112718D0 (en)
WO (1) WO2013014405A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197158A1 (en) * 2016-05-11 2017-11-16 Leuvas Therapeutics Blockade of tim-1 pathways and p-selectin pathways in treatment of neuroinflammatory degenerative disease
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death
EP4210735A1 (en) 2020-09-10 2023-07-19 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 antibodies and methods of use thereof
WO2022208320A1 (en) * 2021-03-29 2022-10-06 Vascular Biogenics Ltd. Motile sperm domain containing protein 2, integrin beta2 and cd63

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117432A2 (en) * 2006-03-30 2007-10-18 The Regents Of The University Of Michigan Methods and compositions for modulating angiogenesis and tumor growth
WO2011029823A1 (en) * 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO2005007695A2 (en) 2003-07-14 2005-01-27 Beth Israel Deaconess Medical Center, Inc. Anti-cd63 antibodies and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117432A2 (en) * 2006-03-30 2007-10-18 The Regents Of The University Of Michigan Methods and compositions for modulating angiogenesis and tumor growth
WO2011029823A1 (en) * 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BJÖRN PETRI ET AL: "The physiology of leukocyte recruitment: an in vivo perspective.", THE JOURNAL OF IMMUNOLOGY, vol. 180, no. 10, 1 May 2008 (2008-05-01), pages 6439 - 6446, XP055047154, ISSN: 0022-1767 *
E. L. DOYLE ET AL: "CD63 is an essential cofactor to leukocyte recruitment by endothelial P-selectin", BLOOD, vol. 118, no. 15, 13 October 2011 (2011-10-13), pages 4265 - 4273, XP055046518, ISSN: 0006-4971, DOI: 10.1182/blood-2010-11-321489 *
HAI-BO WANG ET AL: "P-selectin primes leukocyte integrin activation during inflammation", NATURE IMMUNOLOGY, vol. 8, no. 8, 1 August 2007 (2007-08-01), pages 882 - 892, XP055046717, ISSN: 1529-2908, DOI: 10.1038/ni1491 *
JOCKERS J J ET AL: "Different expression of adhesion molecules and tetraspanins of monocytes of patients with atopic eczema", ALLERGY, WILEY-BLACKWELL PUBLISHING LTD, UNITED KINGDOM, vol. 61, no. 12, 1 December 2006 (2006-12-01), pages 1419 - 1422, XP009138950, ISSN: 0105-4538, [retrieved on 20060817], DOI: 10.1111/J.1398-9995.2006.01191.X *
KIMBERLY J. HARRISON-LAVOIE ET AL: "P-Selectin and CD63 Use Different Mechanisms for Delivery to Weibel-Palade Bodies", TRAFFIC, vol. 7, no. 6, 1 June 2006 (2006-06-01), pages 647 - 662, XP055046522, ISSN: 1398-9219, DOI: 10.1111/j.1600-0854.2006.00415.x *
L. KALLQUIST ET AL: "The tetraspanin CD63 is involved in granule targeting of neutrophil elastase", BLOOD, vol. 112, no. 8, 15 October 2008 (2008-10-15), pages 3444 - 3454, XP055046526, ISSN: 0006-4971, DOI: 10.1182/blood-2007-10-116285 *
MAYADAS T N ET AL: "Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice", CELL, CELL PRESS, US, vol. 74, no. 3, 13 August 1993 (1993-08-13), pages 541 - 554, XP023913412, ISSN: 0092-8674, [retrieved on 19930813], DOI: 10.1016/0092-8674(93)80055-J *
MCKENZIE MARCUS E ET AL: "Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets", BLOOD COAGULATION & FIBRINOLYSIS, RAPID COMMUNICATIONS, OXFORD, OXFORD, GB, vol. 14, no. 3, 1 April 2003 (2003-04-01), pages 249 - 253, XP008158590, ISSN: 0957-5235 *
R. S. SCOTLAND: "C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 102, no. 40, 1 January 2005 (2005-01-01), pages 14452 - 14457, XP055046654, ISSN: 0027-8424, DOI: 10.1073/pnas.0504961102 *
SZEKANECZ Z ET AL: "Therapeutic inhibition of leukocyte recruitment in inflammatory diseases", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 4, no. 4, 1 August 2004 (2004-08-01), pages 423 - 428, XP008090734, ISSN: 1471-4892 *
ZSUZSA SIMON ET AL: "Protein phosphatase inhibitor calyculin - A modulates activation markers in TRAP-stimulated human platelets", PLATELETS, TAYLOR AND FRANCIS GROUP, EDINBURGH, vol. 21, no. 7, 1 January 2010 (2010-01-01), pages 555 - 562, XP008158600, ISSN: 0953-7104 *

Also Published As

Publication number Publication date
WO2013014405A2 (en) 2013-01-31
GB201112718D0 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
EP2705419A4 (en) Database system and method
WO2012106735A3 (en) Plasma-assisted skin treatment
IL227426A0 (en) System, method, and article to prompt behavior change
EP2883172A4 (en) High performance real-time relational database system and methods for using same
EP2774380A4 (en) Method and system for stereo gaze tracking
IL216056A0 (en) Combined database system and method
EP2775955B8 (en) Milling block, method for producing partial or total prostheses and milling block system
EP2739224A4 (en) System and method for cold plasma therapy
EP3050994A4 (en) Non-quenched and tempered steel and manufacturing method therefor
EP3050993A4 (en) Non-quenched and tempered steel and manufacturing method therefor
WO2012129341A3 (en) Disease detection in plants
SG11201404555WA (en) Multi-source, multi-dimensional, cross-entity, multimedia database platform apparatuses, methods and systems
WO2012116010A3 (en) Antibiotic tolerance inhibitors
EP2690188A4 (en) Austenite system alloy pipe and manufacturing method thereof
EP2789704A4 (en) Bearing components, rolling bearing, and methods for producing same
EP3050995A4 (en) Non-quenched and tempered steel and manufacturing method therefor
EP2665147A4 (en) High-pressure equipment system for rolling stock, and rolling stock
WO2013010034A3 (en) Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers
MX2012013740A (en) Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin.
WO2013014405A3 (en) Methods of inhibiting inflammation comprising inhibiting cd63
EP3050991A4 (en) Non-quenched and tempered steel and manufacturing method therefor
SG10201705091YA (en) METHOD FOR PRODUCING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID DERIVATIVE, AND METHOD FOR PURIFYING cis-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID
GB2495825B (en) Filters, systems and methods for reducing can velocity
HK1219269A1 (en) Compound and method for producing same, as well as method for producing oseltamivir phosphate
ZA201305380B (en) Method of and system for sporting event betting

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12753157

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12753157

Country of ref document: EP

Kind code of ref document: A2